Clinical trial Recruiting at 1 site Interventional Ages 20 to 40

Hand function after TECAR therapy for post-burn carpal tunnel syndrome

Official title: Effect of Transfer Energy Capacitive and Resistive on Carpal Tunnel Syndrome Post Burn

Run by Cairo University · NCT07660328 · Data updated 2026-11-12

This study tests whether TECAR therapy can improve hand function and reduce pain for adults with carpal tunnel syndrome that developed after a hand burn.

Quick facts

Study typeInterventional
Ages20 Years to 40 Years
SexAll
Enrollment52 (estimated)
SponsorCairo University
Academic / other
Locations1 site (Al Mansurah, Mansoura)
StatusRecruiting
StartedAugust 9, 2026
Main results expectedOctober 30, 2026
Study endsDecember 1, 2026
Registry record updatedOctober 28, 2026
Trial IDNCT07660328 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 20–40 with mild–moderate post-burn CTS following a 20–25% TBSA burn who consent to participate.

Probably not a fit

Patients with severe CTS, other neuromuscular conditions, or contraindications to TECAR or rehabilitation may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In adults aged 20–40 with mild to moderate post-burn carpal tunnel syndrome, the study delivers TECAR therapy alongside standard hand rehabilitation to see if nerve-related symptoms and hand function improve. The trial plans to enroll 52 participants and uses measures such as the Boston Carpal Tunnel Questionnaire, pain scores, and a handgrip dynamometer to track changes. Outcomes focus on pain reduction, symptom severity, and functional ability over the treatment period. Prior evidence suggests TECAR may help CTS symptoms, but its effects in post-burn CTS require confirmation.

Why it matters

Potential benefit: If successful, TECAR therapy could lessen pain and improve hand function for people affected by post-burn CTS.

How similar studies have gone: Previous studies in idiopathic CTS showed symptom improvements with TECAR, but benefits in post-burn CTS are not yet well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participant is between 20 and 40 years of age.
* Diagnosed with mild to moderate carpal tunnel syndrome (CTS).
* History of an upper limb burn, with the percentage of the Total Body Surface Area (TBSA) ranging from 20% to 25%.
* Upper limb burn is diagnosed as a 2nd or 3rd-degree burn complicated with carpal tunnel syndrome.
* Carpal tunnel syndrome diagnosis is clinically confirmed using physical examination, including a positive Tinel's sign and positive Phalen's test.
* Participant provides written informed consent before enrollment.

Exclusion Criteria:

* History of double crush syndrome, cervical radiculopathy, or fibromyalgia.
* History of wrist fracture or distal radius fracture.
* Diagnosis of systemic or local diseases that contribute to peripheral neuropathy, including Diabetes Mellitus or rheumatoid arthritis (RA).
* Diagnosis of hypothyroidism, skin diseases, or peripheral vascular diseases.
* Current or past history of cancer.
* Use of a hand or wrist splint within the past three months.
* Presence of an implanted pacemaker or electrical prosthesis.

Where it's running

  • QWAM physio clinic
    Al Mansurah, Mansoura, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.